Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Christina, Reitmann"'
Autor:
Jocelyn Gilmartin, Ying Guo, Walter K. Kraft, Li Fan, Rachael Liu, Christina Reitmann, Ilias Triantafyllou, Marian Iwamoto, Ka Lai Yee, Matt S. Anderson
Publikováno v:
Antiviral Therapy. 24:443-450
Background Doravirine (DOR) is a novel non-nucleoside reverse transcriptase inhibitor available as a single tablet and a three-drug combination with lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) to treat HIV-1 infection. These analyses ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8b6208c1dfc8b03a031f06a875190be
https://doi.org/10.3851/imp3324
https://doi.org/10.3851/imp3324
Autor:
Patricia Jumes, Lynn Webster, Zifang Guo, Wendy W. Yeh, Luzelena Caro, Pavan Vaddady, Monika Martinho, Dennis Wolford, Deborah Panebianco, Marian Iwamoto, Hwa-Ping Feng, Christina Reitmann, Iain Fraser, Joan R. Butterton, Robert Valesky, William L. Marshall, Fang Liu
Publikováno v:
Clinical and Translational Science. 11:553-561
We conducted two phase I trials to evaluate the pharmacokinetic interactions between elbasvir (EBR), grazoprevir (GZR), and methadone (MK-8742-P010 and MK-5172-P030) in non-hepatitis C virus (HCV)-infected participants on methadone maintenance therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4041f4cac0090471d4c66213680894b4
https://doi.org/10.1111/cts.12564
https://doi.org/10.1111/cts.12564
Autor:
William L. Marshall, Luzelena Caro, Jocelyn Gilmartin, Dennis Wolford, Zifang Guo, April M. Barbour, Monika Martinho, Christina Reitmann, Lynn Webster, Pavan Vaddady, Deborah Panebianco, Iain Fraser, Wendy W. Yeh, Marian Iwamoto, Fang Liu, Patricia Jumes, Robert Valesky, Joan R. Butterton, Hwa-Ping Feng
Publikováno v:
Clinical and Translational Science. 11:562-572
The aims of these phase I trials were to evaluate the pharmacokinetic interaction between elbasvir (EBR) or grazoprevir (GZR) and buprenorphine/naloxone (BUP/NAL). Trial 1 was a single-dose trial in healthy participants. Trial 2 was a multiple-dose t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e324372a9b0b7cf69723f4699e0b4e4c
https://doi.org/10.1111/cts.12565
https://doi.org/10.1111/cts.12565
Autor:
Hwa-Ping, Feng, Zifang, Guo, Luzelena, Caro, William L, Marshall, Fang, Liu, Deborah, Panebianco, Pavan, Vaddady, Christina, Reitmann, Patricia, Jumes, Dennis, Wolford, Iain, Fraser, Robert, Valesky, Monika, Martinho, Joan R, Butterton, Marian, Iwamoto, Lynn, Webster, Wendy W, Yeh
Publikováno v:
Clinical and Translational Science
We conducted two phase I trials to evaluate the pharmacokinetic interactions between elbasvir (EBR), grazoprevir (GZR), and methadone (MK‐8742‐P010 and MK‐5172‐P030) in non‐hepatitis C virus (HCV)‐infected participants on methadone mainte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1956c4bacf8d512fb1913d5414f9c13f
https://pubmed.ncbi.nlm.nih.gov/30040872
https://pubmed.ncbi.nlm.nih.gov/30040872
Autor:
Iain P. Fraser, Wendy W. Yeh, Naoto Uemura, Peter W Angus, William B. Smith, Edward Gane, Luzelena Caro, Zifang Guo, Joan R. Butterton, Maureen Ho, Thomas Marbury, Christina Reitmann, Jennifer Talaty, Christine Fandozzi, Marian Iwamoto, Deborah Panebianco, Larissa Wenning
Grazoprevir (GZR) plus elbasvir is an approved treatment for chronic infection with hepatitis C virus (HCV) genotype 1 or 4. HCV infection complications include liver cirrhosis, end-stage liver disease, and hepatocellular carcinoma. The objective of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5fdd14986b02b15529a39955aaba00e
https://europepmc.org/articles/PMC5700330/
https://europepmc.org/articles/PMC5700330/
Autor:
Christina Reitmann, Dennis Wolford, Kenneth C. Lasseter, David E. Gutstein, Rebecca E Wrishko, William D. Hanley, Joanna Udo de Haes, K Chris Min, Thomas Marbury
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics.
AIMS Sugammadex rapidly reverses moderate and deep rocuronium- or vecuronium-induced neuromuscular blockade at doses of 4 mg/kg and 2 mg/kg, respectively. Sugammadex is renally eliminated. This study evaluated the pharmacokinetics of sugammadex in su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2458f78b23b93032921eaad015b19a64
https://doi.org/10.5414/cp203025
https://doi.org/10.5414/cp203025
Autor:
Robert B. Nachbar, John A. Wagner, Deborah Panebianco, Valentin S. Moiseev, Zhanna Kobalava, Edward Gane, Christina Reitmann, Sorin Visan, Kristien Van Dyck, Frank J. Dutko, Martine Robberechts, Inge De Lepeleire, Wendy W. Yeh, Andreas Hüser, Zifang Guo, Christian Schwabe, Joan R. Butterton, Edward O'Mara, Markus Uhle, Iain P. Fraser, Xiaobi Huang, Nelea Ghicavii, Patricia Jumes, Serghei Popa, Amelia S. Petry, Frank Wagner
Publikováno v:
Clinical Therapeutics. 40:704-718.e6
Purpose Elbasvir (MK-8742) and grazoprevir (MK-5172; Merck & Co, Inc, Kenilworth, New Jersey) are hepatitis C virus (HCV)-specific inhibitors of the nonstructural protein 5A phosphoprotein and the nonstructural protein 3/4A protease, respectively. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::859e887a63702d1bb18e52d8097ed5ca
https://doi.org/10.1016/j.clinthera.2018.03.002
https://doi.org/10.1016/j.clinthera.2018.03.002